statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for EXEL
 DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Nov 2021RBC CapitalMaintainsOutperform Nov 2021HC Wainwright & Co.MaintainsBuy
 View More Analyst Ratings...

The Analyst Verdict: Exelixis In The Eyes Of 5 Experts

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and...

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT...

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024

What Analysts Are Saying About Exelixis Stock

Exelixis (NASDAQ:EXEL - Get Free Report) and JATT Acquisition (NYSE:JATT - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based...

Analyzing Exelixis (NASDAQ:EXEL) and JATT Acquisition (NYSE:JATT)

An update from Exelixis (EXEL) is now available. Jacqueline Wright has announced that she will not seek re-election to Exelixis, Inc.'s Board of Di...

Jacqueline Wright to Exit Exelixis Board in 2024

Exelixis, Inc. (NASDAQ:EXEL  Get Free Report) Director Alan M. Garber sold 19,205 shares of the businesss stock in a transaction that occurred on Thursday, March 21st. The shares were...

Exelixis, Inc. (NASDAQ:EXEL) Director Sells $461,112.05 in Stock

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024...

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Hudson Bay Capital Management LP lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL  Free Report) by 7.7% during the third quarter, according to the company in its most recent...

Hudson Bay Capital Management LP Has $2.62 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Ameriprise Financial Inc. raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL  Free Report) by 10.7% during the third quarter, according to the company in its most recent 13F filing...

Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Ameriprise Financial Inc.

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Watchers	12,013
52-Wk Low	$18.52
52-Wk High	$24.34

Volume	2.16M
52-Wk High	$24.34
52-Wk Low	$18.52

EXEL Exelixis Inc

About

Feed

News

Sentiment

Earnings

Fundamentals